Literature DB >> 31603075

Intermediate uveitis in a child with phosphatase and tensin homolog gene mutation and Bannayan-Riley-Ruvalcaba syndrome.

Daphna Prat1,2, Iris Ben Bassat Mizrachi1,2, Vicktoria Vishnevskia-Dai1,2.   

Abstract

Bannayan-Riley-Ruvalcaba syndrome (BRRS) is a congenital disorder characterised by macrocephaly, multiple hamartomas, lipomas, and pigmented macules of the glans penis. Intermediate uveitis is characterised by chronic inflammatory cells aggregates on the pars plana (snowbanks) and within the vitreous cavity (snowballs). We describe what we believe to be the first case of intermediate uveitis associated with BRRS. Early examination under anaesthesia should be considered in the management of young children diagnosed with this syndrome in order to provide appropriate ocular evaluation, treatment and follow-up. Further research is needed to establish a better understanding of the ophthalmic manifestations of this syndrome. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  neuro genetics; neurology; ophthalmology

Mesh:

Substances:

Year:  2019        PMID: 31603075      PMCID: PMC6381972          DOI: 10.1136/bcr-2017-224079

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  11 in total

1.  Proliferative retinopathy in Cowden syndrome.

Authors:  Qasim Mansoor; David H W Steel
Journal:  BMJ Case Rep       Date:  2012-03-08

2.  Clinicopathologic and molecular analysis of a choroidal pigmented schwannoma in the context of a PTEN hamartoma tumor syndrome.

Authors:  Giulia Venturini; Alexandre P Moulin; Manuel Deprez; Sylvie Uffer; Armand Bottani; Leonidas Zografos; Carlo Rivolta
Journal:  Ophthalmology       Date:  2012-01-26       Impact factor: 12.079

3.  Autoimmunity, intestinal lymphoid hyperplasia, and defects in mucosal B-cell homeostasis in patients with PTEN hamartoma tumor syndrome.

Authors:  Mario Heindl; Norman Händel; Joanne Ngeow; Janina Kionke; Christian Wittekind; Manja Kamprad; Anne Rensing-Ehl; Stephan Ehl; Julia Reifenberger; Christoph Loddenkemper; Jochen Maul; Albrecht Hoffmeister; Stefan Aretz; Wieland Kiess; Charis Eng; Holm H Uhlig
Journal:  Gastroenterology       Date:  2012-01-20       Impact factor: 22.682

4.  Analysis of clinical features and visual outcomes of pars planitis.

Authors:  Nilufer Berker; Emine Sen; Ufuk Elgin; Cemile Ucgul Atilgan; Erdem Dursun; Pelin Yilmazbas
Journal:  Int Ophthalmol       Date:  2017-04-07       Impact factor: 2.031

5.  Lifetime cancer risks in individuals with germline PTEN mutations.

Authors:  Min-Han Tan; Jessica L Mester; Joanne Ngeow; Lisa A Rybicki; Mohammed S Orloff; Charis Eng
Journal:  Clin Cancer Res       Date:  2012-01-15       Impact factor: 12.531

Review 6.  PTEN hamartoma tumor syndromes.

Authors:  Gideon M Blumenthal; Phillip A Dennis
Journal:  Eur J Hum Genet       Date:  2008-09-10       Impact factor: 4.246

7.  Cowden syndrome and Bannayan Riley Ruvalcaba syndrome represent one condition with variable expression and age-related penetrance: results of a clinical study of PTEN mutation carriers.

Authors:  K L Lachlan; A M Lucassen; D Bunyan; I K Temple
Journal:  J Med Genet       Date:  2007-05-25       Impact factor: 6.318

8.  Prevalence of Noninfectious Uveitis in the United States: A Claims-Based Analysis.

Authors:  Jennifer E Thorne; Eric Suhler; Martha Skup; Samir Tari; Dendy Macaulay; Jingdong Chao; Arijit Ganguli
Journal:  JAMA Ophthalmol       Date:  2016-11-01       Impact factor: 7.389

9.  Critical roles of Pten in B cell homeostasis and immunoglobulin class switch recombination.

Authors:  Akira Suzuki; Tsuneyasu Kaisho; Minako Ohishi; Manae Tsukio-Yamaguchi; Takeshi Tsubata; Pandelakis A Koni; Takehiko Sasaki; Tak Wah Mak; Toru Nakano
Journal:  J Exp Med       Date:  2003-03-03       Impact factor: 14.307

10.  Cowden's syndrome with immunodeficiency.

Authors:  Michael J Browning; Anita Chandra; Valentina Carbonaro; Klaus Okkenhaug; Julian Barwell
Journal:  J Med Genet       Date:  2015-08-05       Impact factor: 6.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.